The 525mg or 700mg with combo is probably the next
Post# of 148294
(Total Views: 365)
Posted On: 06/14/2019 8:51:52 AM
The 525mg or 700mg with combo is probably the next biggest news. That will allow them to firm up the timelimes for the BLA. Maybe the presentation next week tells us more about this.
https://seekingalpha.com/news/3469853-key-eve...hcare?dr=1
Key events next week - healthcare
Noteworthy events during the week of June 16 - 22 for healthcare investors.
SUNDAY (6/16): Keystone Symposia on Molecular and Cellular Biology, Neurodegenerative Diseases, Keystone, CO (5 days). ProMIS Neurosciences (OTCQB:ARFXF): Data on PMN310 in Alzheimer's.
World Congress on Parkinson's Disease and Related Disorders, Montreal (4 days).
MONDAY (6/17): FDA action date for Merck's (NYSE:MRK) Keytruda for treatment-resistant small cell lung cancer.
TUESDAY (6/18): IQVIA (NYSE:IQV): Analyst & investor event, NYC.
International Conference on Malignant Lymphoma, Lugano, Switzerland (5 days). BeiGene (NASDAQ:BGNE): Four presentations on zanubrutinib. Seattle Genetics (NASDAQ:SGEN): Updated Adcetris data.
Medicenna Therapeutics (OTCQB:MDNAF): KOL event on MDNA55 in recurrent glioblastoma.
WEDNESDAY (6/19): FDA advisory committee meeting on the long-term safety of paclitaxel-coated balloons and stents. Related companies: Boston Scientific (NYSE:BSX), Medtronic (NYSE:MDT), Becton, Dickinson (NYSE:BDX), Abbott (NYSE:ABT).
THURSDAY (6/20): ASM Microbe, San Francisco (5 days). Matinas BioPharma (NYSEMKT:MTNB): Preclinical data on MAT2501. SCYNEXIS (NASDAQ:SCYX): Nine presentations on ibrexafungerp. Cidara Therapeutics (NASDAQ:CDTX): New data on rezafungin and CB-012. Entasis Therapeutics (NASDAQ:ETTX): Data on ETX2514SUL, ETX0282CPDP and zoliflodacin. T2 Biosystems (NASDAQ:TTOO): Showcase event for T2MR technology, latest data on T2Bacteria Panel. CytoDyn (OTCQB:CYDY): Phase 3 data on PRO 140 in HIV. OpGen (NASDAQ:OPGN): Data from Acuitas AMR Gene Panel and Acuitas Lighthouse Software.
QIAGEN (NYSE:QGEN): Analyst & Investor Day, NYC.
FDA action date for Merck's (MRK) Keytruda + Pfizer's (NYSE
FE) Inlyta in first-line renal cell carcinoma.
Canopy Growth (NYSE:CGC): FQ4 results (after the close).
FRIDAY (6/21): FDA action date for Agios Pharmaceuticals' (NASDAQ:AGIO) Tibsovo for IDH1-positive AML.
Epizyme (NASDAQ:EPZM): Conference call to discuss Phase 2 data on tazemetostat in relapsed/refractory follicular lymphoma.
SATURDAY (6/22): Society of Nuclear Medicine and Molecular Imaging Annual Meeting, Anaheim, CA (4 days). Progenics Pharmaceuticals (NASDAQ GNX): Six abstracts on Azedra.
Peripheral Nerve Society Annual Meeting, Genoa, Italy (5 days). Alnylam Pharmaceuticals (NASDAQ:ALNY): Onpattro post hoc data.
https://seekingalpha.com/news/3469853-key-eve...hcare?dr=1
Key events next week - healthcare
Noteworthy events during the week of June 16 - 22 for healthcare investors.
SUNDAY (6/16): Keystone Symposia on Molecular and Cellular Biology, Neurodegenerative Diseases, Keystone, CO (5 days). ProMIS Neurosciences (OTCQB:ARFXF): Data on PMN310 in Alzheimer's.
World Congress on Parkinson's Disease and Related Disorders, Montreal (4 days).
MONDAY (6/17): FDA action date for Merck's (NYSE:MRK) Keytruda for treatment-resistant small cell lung cancer.
TUESDAY (6/18): IQVIA (NYSE:IQV): Analyst & investor event, NYC.
International Conference on Malignant Lymphoma, Lugano, Switzerland (5 days). BeiGene (NASDAQ:BGNE): Four presentations on zanubrutinib. Seattle Genetics (NASDAQ:SGEN): Updated Adcetris data.
Medicenna Therapeutics (OTCQB:MDNAF): KOL event on MDNA55 in recurrent glioblastoma.
WEDNESDAY (6/19): FDA advisory committee meeting on the long-term safety of paclitaxel-coated balloons and stents. Related companies: Boston Scientific (NYSE:BSX), Medtronic (NYSE:MDT), Becton, Dickinson (NYSE:BDX), Abbott (NYSE:ABT).
THURSDAY (6/20): ASM Microbe, San Francisco (5 days). Matinas BioPharma (NYSEMKT:MTNB): Preclinical data on MAT2501. SCYNEXIS (NASDAQ:SCYX): Nine presentations on ibrexafungerp. Cidara Therapeutics (NASDAQ:CDTX): New data on rezafungin and CB-012. Entasis Therapeutics (NASDAQ:ETTX): Data on ETX2514SUL, ETX0282CPDP and zoliflodacin. T2 Biosystems (NASDAQ:TTOO): Showcase event for T2MR technology, latest data on T2Bacteria Panel. CytoDyn (OTCQB:CYDY): Phase 3 data on PRO 140 in HIV. OpGen (NASDAQ:OPGN): Data from Acuitas AMR Gene Panel and Acuitas Lighthouse Software.
QIAGEN (NYSE:QGEN): Analyst & Investor Day, NYC.
FDA action date for Merck's (MRK) Keytruda + Pfizer's (NYSE
FE) Inlyta in first-line renal cell carcinoma. Canopy Growth (NYSE:CGC): FQ4 results (after the close).
FRIDAY (6/21): FDA action date for Agios Pharmaceuticals' (NASDAQ:AGIO) Tibsovo for IDH1-positive AML.
Epizyme (NASDAQ:EPZM): Conference call to discuss Phase 2 data on tazemetostat in relapsed/refractory follicular lymphoma.
SATURDAY (6/22): Society of Nuclear Medicine and Molecular Imaging Annual Meeting, Anaheim, CA (4 days). Progenics Pharmaceuticals (NASDAQ
GNX): Six abstracts on Azedra. Peripheral Nerve Society Annual Meeting, Genoa, Italy (5 days). Alnylam Pharmaceuticals (NASDAQ:ALNY): Onpattro post hoc data.
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼